Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome

Thrombosis and Haemostasis

Volumn 115, Issue 2, 2016, Pages 237-239

  Vergallo, Rocco ^a   Aguirre, Aaron D ^b   Abtahian, Farhad ^a   Minami, Yoshiyasu ^a   Soeda, Tsunenari ^a   Chatzizisis, Yiannis S ^b   Croce, Kevin ^b   Jang, Ik Kyung ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; ENOXAPARIN; LUPUS ANTICOAGULANT; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; COMPUTED TOMOGRAPHY SCANNER; CORONARY ARTERY ATHEROSCLEROSIS; DEEP VEIN THROMBOSIS; HEART INFARCTION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; THROMBUS ASPIRATION; YOUNG ADULT; COMPLICATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; PATHOPHYSIOLOGY; RECURRENT DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; THROMBOSIS;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; ST ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; THROMBOSIS; TOMOGRAPHY, OPTICAL COHERENCE; YOUNG ADULT;

EID: 84957111302     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-05-0412     Document Type: Article

References (8)

1. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033–1044.
2. George J, Harats D, Gilburd B, et al. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor- deficient mice. Circulation 2000; 102: 1822–1827.
3. Soeda T, Uemura S, Park SJ, et al. Incidence and Clinical Significance of Post-Stent OCT Findings: One Year Follow-Up Study From a Multicenter Registry. Circulation 2015; Epub ahead of print.
4. Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Reumatol 2015; Epub ahead of print.
5. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 2011; 20: 206–218.
6. Chighizola CB, Moia M, Meroni PL. New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 2014; 23: 1279–1282.
7. Signorelli F, Nogueira F, Domingues V, et al. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 2015; Epub ahead of print.
8. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drugeluting stents. N Engl J Med 2014; 371: 2155–2166.